Overview Dividends

(BNTX) BioNTech SE - Ratings and Ratios

Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US09075V1026

Oncology Vaccines,Checkpoint Antibodies,MRNA Therapies,Cellular Immunotherapies

EPS (Earnings per Share)

EPS Growth (3y CAGR): -38.26%
EPS Trend (3y Corr): -54.9%

Last SUE: 0.77σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): -31.38%
Revenue Trend (3y Corr): -26.8%

Last SUE: 1.27σ
Qual. Beats: 1

Risk via 10d forecast
Volatility	48.0%
Value at Risk 5%th	65.5%
Relative Tail Risk	-16.94%

Reward TTM
Sharpe Ratio	-0.02
Alpha	-16.45

Character TTM
Hurst Exponent	0.352
Beta	0.919
Beta Downside	0.399

Drawdowns 3y
Max DD	57.88%
Mean DD	41.44%
Median DD	42.83%

Description: BNTX BioNTech SE October 14, 2025

BioNTech SE (NASDAQ:BNTX) is a German biotechnology firm focused on developing mRNA-based immunotherapies for cancer and infectious diseases. Its pipeline includes more than 20 candidates across all clinical phases, notably BNT111 (Phase 2 melanoma), BNT113 (Phase 2 head-and-neck squamous cell carcinoma), BNT116 (Phase 1 non-small cell lung cancer), and the multi-indication BNT122/RO7198457 (Phase 2 adjuvant urothelial carcinoma, colorectal, pancreatic and advanced melanoma). The company also advances late-stage assets such as BNT311/GEN1046 (Phase 3 solid tumors) and BNT327 (spanning Phase 1-3 trials for small-cell lung cancer, TNBC, neuroendocrine neoplasms, and hepatocellular carcinoma).

Key recent metrics: as of Q2 2024, BioNTech reported €2.9 billion in revenue, driven primarily by its COVID-19 vaccine partnership with Pfizer, while cash and equivalents stood at €4.1 billion, providing a runway of over three years at current burn rates. The mRNA platform’s scalability and the broader biotech sector’s 12-month forward-looking P/E median of ~30× underscore both high growth potential and valuation pressure. A material driver of future earnings is the ability to leverage the existing mRNA manufacturing network for oncology candidates, which could reduce cost-of-goods-sold (COGS) by up to 20 % relative to early-stage trials.

For a deeper quantitative assessment, the ValueRay platform offers a granular view of BNTX’s risk-adjusted upside.

BNTX Stock Overview

Market Cap in USD	24,654m
Sub-Industry	Biotechnology
IPO / Inception	2019-10-10
Return 12m vs S&P 500	-15.1%
Analyst Rating	4.38 of 5

BNTX Dividends

Currently no dividends paid

BNTX Growth Ratios

Metric	Value
CAGR 3y	-14.57%
CAGR/Max DD Calmar Ratio	-0.25
CAGR/Mean DD Pain Ratio	-0.35
Current Volume	1179.7k
Average Volume	607.9k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-571.6m TTM) > 0 and > 6% of Revenue (6% = 189.2m TTM)

FCFTA -0.03 (>2.0%) and ΔFCFTA -6.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 431.7% (prev 525.1%; Δ -93.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.02 (>3.0%) and CFO -336.1m > Net Income -571.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 7.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (239.2m) change vs 12m ago -2.21% (target <= -2.0% for YES)

Gross Margin 82.49% (prev 84.31%; Δ -1.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 14.41% (prev 13.57%; Δ 0.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -28.11 (EBITDA TTM -103.3m / Interest Expense TTM 17.3m) >= 6 (WARN >= 3)

Altman Z'' 13.60

(A) 0.64 = (Total Current Assets 15.83b - Total Current Liabilities 2.22b) / Total Assets 21.34b

(B) 0.86 = Retained Earnings (Balance) 18.27b / Total Assets 21.34b

warn (B) unusual magnitude: 0.86 — check mapping/units

(D) 6.45 = Book Value of Equity 18.49b / Total Liabilities 2.86b

Total Rating: 13.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 17.59

1. Piotroski 1.0pt

2. FCF Yield -7.91%

3. FCF Margin -17.85%

4. Debt/Equity 0.01

5. Debt/Ebitda 95.33

6. ROIC - WACC (= -19.89)%

7. RoE -3.04%

8. Rev. Trend -26.77%

9. EPS Trend -54.92%

What is the price of BNTX shares?

As of November 21, 2025, the stock is trading at USD 96.97 with a total of 1,179,676 shares traded.
Over the past week, the price has changed by -6.65%, over one month by -10.17%, over three months by -12.88% and over the past year by -5.06%.

Is BNTX a buy, sell or hold?

BioNTech SE has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy BNTX.

Strong Buy: 13
Buy: 3
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BNTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	136.7	41%
Analysts Target Price	136.7	41%
ValueRay Target Price	89.6	-7.6%

BNTX Fundamental Data Overview November 20, 2025

Market Cap EUR = 21.40b (24.65b USD * 0.8679 USD.EUR)
P/E Forward = 7.0373
P/S = 7.8204
P/B = 1.1504
P/EG = 0.0449
Beta = 1.308
Revenue TTM = 3.15b EUR
EBIT TTM = -486.7m EUR
EBITDA TTM = -103.3m EUR
Long Term Debt = 192.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 53.4m EUR (from shortTermDebt, last quarter)
Debt = 245.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.85b EUR (from netDebt column, last quarter)
Enterprise Value = 7.11b EUR (21.40b + Debt 245.4m - CCE 14.53b)
Interest Coverage Ratio = -28.11 (Ebit TTM -486.7m / Interest Expense TTM 17.3m)
FCF Yield = -7.91% (FCF TTM -562.7m / Enterprise Value 7.11b)
FCF Margin = -17.85% (FCF TTM -562.7m / Revenue TTM 3.15b)
Net Margin = -18.13% (Net Income TTM -571.6m / Revenue TTM 3.15b)
Gross Margin = 82.49% ((Revenue TTM 3.15b - Cost of Revenue TTM 552.0m) / Revenue TTM)
Gross Margin QoQ = 90.24% (prev 70.71%)
Tobins Q-Ratio = 0.33 (Enterprise Value 7.11b / Total Assets 21.34b)
Interest Expense / Debt = 0.16% (Interest Expense 399.1k / Debt 245.4m)
Taxrate = 216.2% (out of range, set to none) (53.4m / 24.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 7.12 (Total Current Assets 15.83b / Total Current Liabilities 2.22b)
Debt / Equity = 0.01 (Debt 245.4m / totalStockholderEquity, last quarter 18.48b)
Debt / EBITDA = 95.33 (negative EBITDA) (Net Debt -9.85b / EBITDA -103.3m)
Debt / FCF = 17.50 (negative FCF - burning cash) (Net Debt -9.85b / FCF TTM -562.7m)
Total Stockholder Equity = 18.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.68% (Net Income -571.6m / Total Assets 21.34b)
RoE = -3.04% (Net Income TTM -571.6m / Total Stockholder Equity 18.83b)
RoCE = -2.56% (EBIT -486.7m / Capital Employed (Equity 18.83b + L.T.Debt 192.0m))
RoIC = -10.60% (negative operating profit) (EBIT -486.7m / (Assets 21.34b - Curr.Liab 2.22b - Cash 14.53b))
WACC = 9.29% (E(21.40b)/V(21.64b) * Re(9.40%) + (debt cost/tax rate unavailable))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.38%
Fair Price DCF = unknown (Cash Flow -562.7m)
EPS Correlation: -54.92 | EPS CAGR: -38.26% | SUE: 0.77 | # QB: 0
Revenue Correlation: -26.77 | Revenue CAGR: -31.38% | SUE: 1.27 | # QB: 1

Additional Sources for BNTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle